Vertex Pharmaceuticals Inc (VRTX) shareholders
VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 15/3028% above fair value
$542.62−4.41 (-0.81%)
Close on Nov 12, 2026Market cap $137.53BP/E 31.6Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
95.6%
242M of 253M shares
Institutional holders
1,754
193 new, 110 sold out
Net institutional buying
7M
In Q2 2026
Insider trades, 12 months
0 buys · 94 sales
Net sold $164.40M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Capital World Investors | 25,695,015 | 10.10% | 13G (passive) amendment | Mar 31, 2026 |
| BlackRock, Inc. | 21,881,203 | 8.50% | 13G (passive) | Dec 31, 2023 |
| Capital Research Global Investors | 21,139,169 | 8.30% | 13G (passive) amendment | Mar 31, 2026 |
| Vanguard Capital Management | 19,036,076 | 7.49% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of VRTX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Capital World Investors | 26,115,014 | 10.30% | $12.97B | +746,890 | 1.53% |
| BlackRock, Inc. | 24,109,373 | 9.51% | $11.98B | +139,856 | 0.18% |
| Capital Research Global Investors | 19,490,637 | 7.69% | $9.68B | −1,635,327 | 1.35% |
| Vanguard Capital Management LLC | 16,580,713 | 6.54% | $8.24B | +67,903 | 0.18% |
| State Street Corp | 11,871,459 | 4.68% | $5.90B | +141,320 | 0.17% |
| Invesco Ltd. | 8,043,052 | 3.17% | $4.00B | +150,441 | 0.32% |
| JPMorgan Chase & Co | 6,517,600 | 2.57% | $3.26B | −515,556 | 0.18% |
| Geode Capital Management, LLC | 6,017,848 | 2.37% | $2.98B | −121,773 | 0.16% |
| Vanguard Portfolio Management LLC | 4,878,987 | 1.92% | $2.42B | −266,622 | 0.11% |
| Capital International Investors | 4,695,144 | 1.85% | $2.33B | −430,933 | 0.48% |
| Loomis Sayles & Co L P | 3,920,953 | 1.55% | $1.95B | −82,868 | 2.44% |
| Franklin Resources Inc | 3,347,253 | 1.32% | $1.66B | +2,796,121 | 0.36% |
| Wellington Management Group Llp | 3,247,658 | 1.28% | $1.61B | +35,069 | 0.28% |
| Morgan Stanley | 3,242,139 | 1.28% | $1.61B | +53,258 | 0.09% |
| UBS Asset Management Americas Inc | 3,086,683 | 1.22% | $1.53B | +29,287 | 0.28% |
| Bank Of America Corp /De/ | 3,039,178 | 1.20% | $1.51B | +160,995 | 0.10% |
| Alliancebernstein L.P. | 3,019,315 | 1.19% | $1.35B | −891,471 | 0.45% |
| Jennison Associates LLC | 2,998,530 | 1.18% | $1.49B | +258,471 | 0.89% |
| Norges Bank | 2,971,681 | 1.17% | $1.48B | New | 0.15% |
| Ameriprise Financial Inc | 2,604,822 | 1.03% | $1.29B | −28,659 | 0.26% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 1,754 | 242M | 95.6% | 193 / 706 | 618 / 110 | 17M | 10M |
| Q1 2026 | 1,697 | 238M | 93.8% | 155 / 681 | 600 / 105 | 37M | 17M |
| Q4 2025 | 1,669 | 242M | 95.6% | 273 / 619 | 568 / 99 | 23M | 19M |
| Q3 2025 | 1,521 | 239M | 94.2% | 143 / 556 | 614 / 157 | 20M | 23M |
| Q2 2025 | 1,562 | 242M | 95.7% | 121 / 617 | 610 / 149 | 16M | 14M |
| Q1 2025 | 1,615 | 241M | 95.0% | 209 / 637 | 578 / 128 | 16M | 11M |
| Q4 2024 | 1,560 | 237M | 93.5% | 200 / 555 | 616 / 155 | 18M | 23M |
| Q3 2024 | 1,548 | 242M | 95.5% | 123 / 626 | 584 / 106 | 32M | 11M |
| Q2 2024 | 1,549 | 242M | 95.5% | 173 / 662 | 517 / 93 | 14M | 19M |
| Q1 2024 | 1,495 | 248M | 98.0% | 174 / 609 | 518 / 97 | 19M | 15M |
| Q4 2023 | 1,440 | 245M | 96.6% | 244 / 560 | 480 / 61 | 22M | 13M |
| Q3 2023 | 1,279 | 236M | 93.2% | 84 / 534 | 460 / 78 | 8M | 9M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
1,065 funds held VRTX in Q2 2026, 34% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of VRTX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Growth Fund of America | 12,497,307 | 4.93% | $5.59B | 1.55% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 8,058,128 | 3.18% | $4.00B | 0.17% | Jun 30, 2026 |
| Vanguard 500 Index Fund | 6,576,510 | 2.59% | $3.27B | 0.20% | Jun 30, 2026 |
| Investment Co of America | 6,269,142 | 2.47% | $3.11B | 1.69% | Jun 30, 2026 |
| American Balanced Fund | 5,558,357 | 2.19% | $2.76B | 0.96% | Jun 30, 2026 |
| Invesco QQQ Trust, Series 1 | 5,387,574 | 2.13% | $2.68B | 0.55% | Jun 30, 2026 |
| AMCAP Fund | 4,651,898 | 1.84% | $2.08B | 2.14% | May 31, 2026 |
| iShares Core S&P 500 ETF | 3,491,802 | 1.38% | $1.73B | 0.20% | Jun 30, 2026 |
| New Perspective Fund | 3,366,011 | 1.33% | $1.67B | 0.98% | Jun 30, 2026 |
| Fidelity 500 Index Fund | 3,250,444 | 1.28% | $1.45B | 0.17% | May 31, 2026 |
| Vanguard Growth Index Fund | 2,784,526 | 1.10% | $1.38B | 0.36% | Jun 30, 2026 |
| Capital World Growth & Income Fund | 2,338,257 | 0.92% | $1.05B | 0.66% | May 31, 2026 |
| Washington Mutual Investors Fund | 1,975,814 | 0.78% | $942.66M | 0.43% | Jul 31, 2026 |
| Vanguard Health Care Fund | 1,890,142 | 0.75% | $901.79M | 2.36% | Jul 31, 2026 |
| State Street(R) Health Care Select Sector SPDR(R) ETF | 1,793,091 | 0.71% | $890.68M | 2.19% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Reshma Kewalramani | CEO & President, Director | 86,471 | 0.03% | Nov 10, 2026 |
| Jeffrey M. Leiden | Executive Chairman, Director | 35,237 | 0.01% | Feb 26, 2026 |
| Grunsven Jasper van | EVP, CP and NPPO | 8,682 | 0.00% | Sep 10, 2026 |
| Kristen Ambrose | SVP & Chief Accounting Officer | 11,624 | 0.00% | Sep 1, 2026 |
| Amit Sachdev | EVP Chief Patient & Ext Af Off | 74,031 | 0.03% | Jul 23, 2026 |
| Ourania Tatsis | EVP, Chief Reg. & Quality Off. | 53,572 | 0.02% | Jul 23, 2026 |
| Duncan McKechnie | EVP, Chief Commercial Officer | 11,001 | 0.00% | Jul 7, 2026 |
| Joy Liu | EVP and Chief Legal Officer | 19,131 | 0.01% | Jul 6, 2026 |
| Carmen Bozic | EVP and CMO | 15,337 | 0.01% | Jun 30, 2026 |
| Mark E. Bunnage | EVP, Chief Scientific Officer | 7,284 | 0.00% | May 19, 2026 |
| Charles F. Wagner Jr | EVP, CO & FO | 47,042 | 0.02% | Feb 26, 2026 |
| Jonathan Biller | EVP and Chief Legal Officer | 13,659 | 0.01% | Feb 26, 2026 |
| Edward Morrow Atkinson III | EVP, Chief Technical Ops. Off. | 18,432 | 0.01% | Feb 26, 2026 |
| David Altshuler | EVP, Chief Scientific Officer | 34,477 | 0.01% | Jan 26, 2026 |
| Stuart A. Arbuckle | EVP, COO | 63,508 | 0.03% | Jul 2, 2025 |
| Daniel J. Brennan | Director | 795 | 0.00% | Oct 22, 2026 |
| Alan M. Garber | Director | 7,344 | 0.00% | Oct 19, 2026 |
| Bruce I. Sachs | Director | 39,000 | 0.02% | Oct 19, 2026 |
| Michel Lagarde | Director | 1,132 | 0.00% | May 5, 2026 |
| Nancy Thornberry | Director | 2,109 | 0.00% | May 5, 2026 |
| Diana McKenzie | Director | 3,381 | 0.00% | May 5, 2026 |
| Lloyd Carney | Director | 6,315 | 0.00% | May 5, 2026 |
| Sangeeta N. Bhatia | Director | 4,924 | 0.00% | May 5, 2026 |
| Suketu Upadhyay | Director | 1,558 | 0.00% | May 5, 2026 |
| Jennifer Schneider | Director | 2,190 | 0.00% | May 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Reshma Kewalramani CEO & President, Director | Nov 6, 2026 | Sale(10b5-1 plan) | −11,866 | $531.53 | $6.31M | 86,471 |
| Daniel J. Brennan Director | Oct 20, 2026 | Award | +795 | $503.47 | $400.26K | 795 |
| Grunsven Jasper van EVP, CP and NPPO | Sep 8, 2026 | Award | +8,682 | – | – | 8,682 |
| Kristen Ambrose SVP & Chief Accounting Officer | Aug 28, 2026 | Award | +5,000 | – | – | 11,624 |
| Bruce I. Sachs Director | Aug 27, 2026 | Gift | −6,000 | – | – | 39,000 |
| Amit Sachdev EVP Chief Patient & Ext Af Off | Jul 21, 2026 | Award | +8,251 | – | – | 66,512 |
| Ourania Tatsis EVP, Chief Reg. & Quality Off. | Jul 21, 2026 | Award | +8,251 | – | – | 53,572 |
| Ourania Tatsis EVP, Chief Reg. & Quality Off. | Jul 2, 2026 | Sale(10b5-1 plan) | −1,500 | $524.99 | $787.49K | 45,321 |
| Duncan McKechnie EVP, Chief Commercial Officer | Jul 2, 2026 | Sale(10b5-1 plan) | −1,541 | $519.00 | $799.78K | 11,001 |
| Joy Liu EVP and Chief Legal Officer | Jul 1, 2026 | Sale(10b5-1 plan) | −828 | $502.71 | $416.24K | 19,131 |
| Carmen Bozic EVP and CMO | Jun 26, 2026 | Sale(10b5-1 plan) | −596 | $482.50 | $287.57K | 15,337 |
| Carmen Bozic EVP and CMO | Jun 18, 2026 | Sale(10b5-1 plan) | −1,020 | $462.17 | $471.41K | 15,933 |
| Carmen Bozic EVP and CMO | Jun 15, 2026 | Sale(10b5-1 plan) | −4,062 | $450.00 | $1.83M | 16,953 |
| Carmen Bozic EVP and CMO | Jun 5, 2026 | Sale(10b5-1 plan) | −1,745 | $450.00 | $785.25K | 21,015 |
| Joy Liu EVP and Chief Legal Officer | Jun 1, 2026 | Sale(10b5-1 plan) | −828 | $439.91 | $364.25K | 19,959 |
| Carmen Bozic EVP and CMO | May 29, 2026 | Sale(10b5-1 plan) | −1,974 | $450.00 | $888.30K | 22,760 |
| Carmen Bozic EVP and CMO | May 15, 2026 | Sale(10b5-1 plan) | −1,354 | $453.45 | $613.97K | 24,734 |
| Mark E. Bunnage EVP, Chief Scientific Officer | May 15, 2026 | Sale(10b5-1 plan) | −33 | $453.45 | $14.96K | 7,284 |
| Carmen Bozic EVP and CMO | May 12, 2026 | Sale(10b5-1 plan) | −6,988 | $450.00 | $3.14M | 26,088 |
| Sangeeta N. Bhatia Director | May 4, 2026 | Sale(10b5-1 plan) | −318 | $423.73 | $134.75K | 4,924 |
| Nancy Thornberry Director | May 1, 2026 | Returned to company | −398 | – | – | 2,109 |
| Nancy Thornberry Director | May 1, 2026 | Award | +472 | – | – | 2,507 |
| Sangeeta N. Bhatia Director | May 1, 2026 | Award | +943 | – | – | 5,242 |
| Joy Liu EVP and Chief Legal Officer | May 1, 2026 | Sale(10b5-1 plan) | −1,104 | $425.02 | $469.22K | 20,729 |
| Alan M. Garber Director | May 1, 2026 | Award | +472 | – | – | 7,344 |
| Jennifer Schneider Director | May 1, 2026 | Award | +472 | – | – | 2,190 |
| Jennifer Schneider Director | May 1, 2026 | Returned to company | −796 | – | – | 1,394 |
| Suketu Upadhyay Director | May 1, 2026 | Returned to company | −796 | – | – | 1,558 |
| Diana McKenzie Director | May 1, 2026 | Award | +943 | – | – | 3,174 |
| Diana McKenzie Director | May 1, 2026 | Returned to company | −796 | – | – | 2,378 |
| Joy Liu EVP and Chief Legal Officer | Apr 1, 2026 | Sale(10b5-1 plan) | −978 | $449.17 | $439.29K | 21,833 |
| Carmen Bozic EVP and CMO | Mar 27, 2026 | Sale(10b5-1 plan) | −2,329 | $450.95 | $1.05M | 33,076 |
| Carmen Bozic EVP and CMO | Mar 13, 2026 | Sale(10b5-1 plan) | −2,329 | $481.79 | $1.12M | 35,405 |
| Duncan McKechnie EVP, Chief Commercial Officer | Mar 11, 2026 | Sale(10b5-1 plan) | −2,633 | $498.42 | $1.31M | 12,489 |
| Duncan McKechnie EVP, Chief Commercial Officer | Mar 4, 2026 | Sale(10b5-1 plan) | −2,437 | $475.30 | $1.16M | 15,122 |
| Joy Liu EVP and Chief Legal Officer | Mar 2, 2026 | Sale(10b5-1 plan) | −892 | $495.96 | $442.40K | 22,811 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −15,580 | $495.38 | $7.72M | 105,998 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −3,498 | $494.33 | $1.73M | 121,578 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −2,520 | $493.29 | $1.24M | 125,076 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −949 | $491.30 | $466.24K | 127,596 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −2,725 | $490.54 | $1.34M | 128,545 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −5,995 | $496.16 | $2.97M | 100,003 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −1,725 | $496.95 | $857.24K | 98,278 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −460 | $489.32 | $225.09K | 131,270 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −400 | $479.75 | $191.90K | 137,878 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −120 | $481.50 | $57.78K | 137,758 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −240 | $482.84 | $115.88K | 137,518 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −2,510 | $487.13 | $1.22M | 135,008 |
| Reshma Kewalramani CEO & President, Director | Feb 27, 2026 | Sale(10b5-1 plan) | −3,278 | $488.27 | $1.60M | 131,730 |
| Carmen Bozic EVP and CMO | Feb 27, 2026 | Sale(10b5-1 plan) | −2,329 | $480.31 | $1.12M | 37,734 |
| Kristen Ambrose SVP & Chief Accounting Officer | Feb 26, 2026 | Sale(10b5-1 plan) | −357 | $483.36 | $172.56K | 6,624 |
| Ourania Tatsis EVP, Chief Reg. & Quality Off. | Feb 25, 2026 | Sale(10b5-1 plan) | −260 | $486.35 | $126.45K | 46,763 |
| Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | Feb 25, 2026 | Sale(10b5-1 plan) | −668 | $486.35 | $324.88K | 18,432 |
| Jonathan Biller EVP and Chief Legal Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −945 | $486.35 | $459.60K | 13,659 |
| Mark E. Bunnage EVP, Chief Scientific Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −620 | $486.35 | $301.54K | 7,284 |
| Duncan McKechnie EVP, Chief Commercial Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −2,500 | $486.35 | $1.22M | 19,969 |
| Duncan McKechnie EVP, Chief Commercial Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −2,410 | $489.00 | $1.18M | 17,559 |
| Kristen Ambrose SVP & Chief Accounting Officer | Feb 25, 2026 | Sale(10b5-1 plan) | −223 | $486.35 | $108.46K | 6,981 |
| Amit Sachdev EVP Chief Patient & Ext Af Off | Feb 25, 2026 | Sale(10b5-1 plan) | −1,846 | $486.35 | $897.80K | 55,570 |
| Ourania Tatsis EVP, Chief Reg. & Quality Off. | Feb 24, 2026 | Tax withholding | −1,627 | $485.11 | $789.27K | 47,023 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
1.90%
5M shares short
Days to cover
3.4
At 1M shares a day
Change since last report
+12.9%
From 4M shares
Short volume, 20 days
54.6%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Vertex Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 24,619 shares on Sep 24, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Reshma Kewalramani Officer, Director | Nov 6, 2026 | 11,866 | $6.31M | Nov 6, 2026 | ESPP Purchase |
| Bruce I. Sachs Director | Aug 27, 2026 | 1,210 | $662.54K | Aug 27, 2026 | Acquired as a gift |
| Ourania Tatsis Officer | Jul 2, 2026 | 1,500 | $787.49K | Jul 2, 2026 | Restricted Stock Vesting |
| Duncan McKechnie Officer | Jul 2, 2026 | 1,541 | $799.78K | Jul 2, 2026 | Restricted Stock Vesting |
| Joy Liu Officer | Jul 1, 2026 | 828 | $416.24K | Jul 1, 2026 | Restricted Stock Vesting |
| Carmen Bozic Officer | Jun 26, 2026 | 596 | $287.57K | Jun 26, 2026 | Restricted Stock Vesting |
| Carmen Bozic Officer | Jun 18, 2026 | 1,020 | $471.41K | Jun 18, 2026 | Restricted Stock Vesting |
| Carmen Bozic Officer | Jun 15, 2026 | 4,062 | $1.83M | Jun 15, 2026 | Restricted Stock Vesting |
| Carmen Bozic Officer | Jun 5, 2026 | 1,745 | $785.25K | Jun 5, 2026 | Restricted Stock Vesting |
| Joy Liu Officer | Jun 1, 2026 | 828 | $364.25K | Jun 1, 2026 | Restricted Stock Vesting |
| Carmen Bozic Officer | May 29, 2026 | 1,974 | $888.30K | May 29, 2026 | Restricted Stock Vesting |
| Mark E. Bunnage Officer | May 15, 2026 | 33 | $14.96K | May 15, 2026 | ESPP Purchase |
| Carmen Bozic Officer | May 15, 2026 | 1,354 | $613.97K | May 15, 2026 | Restricted Stock Vesting |
| Carmen Bozic Officer | May 12, 2026 | 6,988 | $3.14M | May 12, 2026 | Restricted Stock Vesting |
| Jonathan Biller Officer | May 6, 2026 | 5,193 | $2.20M | May 6, 2026 | Restricted Stock Vesting |
See a number that looks wrong?